theMednetRegister
Ann Surg Oncol 2023 May 19
Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.   

Related Questions

In G1 metastatic GEP-NET with small lesions visible on PET dotatate, very low burden of disease on CT and no clinical symptoms, are there any data to suggest early lanreotide changes natural history of disease and prolongs OS vs observation until symptoms?
New comment by Medical Oncologist at Mayo Clinic ( September 11, 2023)
I would be careful with a h/o SBO, especially of peritoneal mets, and perhaps be more inclined to start therapy but if there was a cause of the SBO (tumor, adhesions, fibrosis...
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
New answer by Medical Oncologist at Mayo Clinic (May 15, 2025)
The first question is always if it is truly unresectable... What is considered unresectable by some might be considered resectable by others, so I always recommend getting an ...
Copyright © 2025 theMednet
All Rights Reserved.